HCWB - HCW Biologics Inc logo

HCW Biologics Inc

HCWB

HCW Biologics Inc. develops immunotherapies targeting chronic inflammation, cancer, and autoimmune diseases. Its lead products include HCW9218 for solid tumors and HCW9302 for autoimmune conditions, alongside various novel biologics for advanced treatments.

⚕️ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago →$1today

Score Overview

1 Year
Score—
Net Growth20.74%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev Trend—
Revenue Consistency—
5 Years
Score4.5
Net Growth50.95%
Net Trend40%
Net Income Consistency—
Rev Growth64.91%
Rev Trend33%
Revenue Consistency—
All Time
Score
Net Growth50.95%
Net Trend40%
Net Income Consistency
Rev Growth64.91%
Rev Trend33%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where HCW Biologics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. HCWB does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 0.78—
1 Year2025-11-17
$ 18.36-95.77%
5 Years2021-11-17
$ 720.00-99.89%
All Time2021-07-20
$ 1.51K-99.95%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 6M-$ 6M$ 955.46K
2025-$ 7M$ 1M
2024$ 2M-$ 30M$ 4M
2023$ 2M-$ 24M$ 3M
2022$ 6M-$ 14M$ 32M
IPO2021$ 4M-$ 12M$ 36M
HCWB - HCW Biologics Inc logo

HCW Biologics Inc fundamental performance

Between 2021 and 2025, net income went from -$ 12M to -$ 7M. Revenue increased in 33% of the years measured; net income in 40%.

HCW Biologics Inc currently holds a 5-year HDB Score of 4.5 out of 10. How the HDB Score is calculated.

Membership

Explore HCWB with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies